Acadia Pharmaceuticals INC Form 4 insider transactions

Adora Ndu, a Director at ACADIA PHARMACEUTICALS INC., increased her beneficial ownership through the vesting of restricted stock units and the grant of new stock options and restricted stock units on May 29, 2025.

Acadia Pharmaceuticals Inc. Director Edmund Harrigan reported the vesting of restricted stock units and the acquisition of new stock options and restricted stock units on May 29, 2025, increasing his direct beneficial ownership of common stock to 35,041 shares.

ACADIA PHARMACEUTICALS Inc. Director Elizabeth A. Garofalo reported the vesting and exercise of restricted stock units, alongside the grant of new stock options and restricted stock units, as part of her compensation.

ACADIA PHARMACEUTICALS Director James M. Daly reported the conversion of restricted stock units into common stock and the grant of new stock options and restricted stock units as part of his compensation.

Acadia Pharmaceuticals Inc. Director Laura Brege reported the exercise of restricted stock units and the grant of new stock options and restricted stock units on May 29, 2025, increasing her beneficial ownership.

Key directors affiliated with Baker Bros. Advisors, Julian C. Baker and Dr. Stephen R. Biggar, have received grants of restricted stock units and non-qualified stock options from Acadia Pharmaceuticals Inc.'s 2024 Equity Incentive Plan.

James Kihara, Principal Accounting Officer at Acadia Pharmaceuticals, reports the sale of 4,000 shares of common stock on May 16, 2025, under a pre-arranged trading plan.

Mark C. Schneyer, EVP and CFO of Acadia Pharmaceuticals, sold 2,000 shares of common stock at $25 per share under a pre-arranged 10b5-1 trading plan.

Principal Accounting Officer James Kihara of Acadia Pharmaceuticals reports the vesting and sale of restricted stock units to cover tax obligations.

Mark Schneyer, EVP and CFO of Acadia Pharmaceuticals, reports the acquisition and disposition of common stock and restricted stock units.

Mark Schneyer, EVP and CFO of Acadia Pharmaceuticals, reports the vesting of restricted stock units and subsequent sale of shares to cover withholding taxes.

James Kihara, Principal Accounting Officer of Acadia Pharmaceuticals, reports the vesting and sale of restricted stock units to cover tax obligations.

Principal Accounting Officer James Kihara reports acquisition and disposal of Acadia Pharmaceuticals stock and stock options.

Mark C. Schneyer, EVP and CFO of Acadia Pharmaceuticals, reports the acquisition of stock options and restricted stock units (RSUs), as well as the sale of shares to cover withholding taxes.

Jennifer J. Rhodes, EVP, Chief Legal Officer, and Secretary of Acadia Pharmaceuticals, reports acquiring shares through the Employee Stock Purchase Plan and stock options and restricted stock units as part of her compensation.

Elizabeth H.Z. Thompson, EVP, Head of Research & Development at Acadia Pharmaceuticals, reports acquisition of stock options and restricted stock units.

CEO Catherine Owen Adams reports acquisition of stock options and restricted stock units in Acadia Pharmaceuticals.

Elizabeth A. Garofalo, a director at Acadia Pharmaceuticals, sold 4,919 shares of common stock at a price of $18.23 on March 5, 2025.

Principal Accounting Officer James Kihara of Acadia Pharmaceuticals reports the vesting of restricted stock units and subsequent sale of shares to cover withholding taxes.

EVP and CFO of Acadia Pharmaceuticals, Mark Schneyer, reports the vesting of restricted stock units and subsequent sale of shares to cover withholding taxes.

Acadia Pharmaceuticals' EVP, Chief Commercial Officer, Thomas Garner, received stock options and restricted stock units as part of the 2024 Equity Incentive Plan.

An Acadia Pharmaceuticals executive, Brendan Teehan, exercised stock options and sold shares to cover tax obligations, according to a recent SEC Form 4 filing.

Principal Accounting Officer James Kihara of Acadia Pharmaceuticals reported the acquisition and sale of company stock, including the vesting of restricted stock units.

Acadia Pharmaceuticals' CFO, Mark C. Schneyer, sold 10,259 shares of common stock at an average price of $16.81 to cover tax obligations related to the vesting of restricted stock units.

Director Adora Ndu reports the vesting and disposal of restricted stock units in Acadia Pharmaceuticals.

Acadia Pharmaceuticals' CEO, Catherine Owen Adams, acquired stock options as a material inducement to her employment, according to a Form 4 filing.

Mark Schneyer, EVP and CFO of Acadia Pharmaceuticals, reports acquisition of shares through vesting of performance stock units and subsequent sale to cover withholding taxes.

EVP, COO, and Head of Commercial Brendan Teehan reports acquisition and disposal of Acadia Pharmaceuticals stock related to vesting of performance stock units and tax obligations.

CEO Stephen Davis of Acadia Pharmaceuticals reports acquisition and disposal of company stock related to performance stock unit vesting and tax obligations.

Elizabeth H.Z. Thompson, EVP, Head of Research & Development at Acadia Pharmaceuticals, reports acquisition of stock options and restricted stock units.